| 104.825 2.485 (2.43%) | 10-15 11:23 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 123.08 |
1-year : | 143.76 |
| Resists | First : | 105.37 |
Second : | 123.08 |
| Pivot price | 100.25 |
|||
| Supports | First : | 99 |
Second : | 95.05 |
| MAs | MA(5) : | 102.41 |
MA(20) : | 100.88 |
| MA(100) : | 99.95 |
MA(250) : | 106.5  |
|
| MACD | MACD : | -0.7 |
Signal : | -1.5 |
| %K %D | K(14,3) : | 88.3 |
D(3) : | 78.5 |
| RSI | RSI(14): 59.2 |
|||
| 52-week | High : | 129.62 | Low : | 81.38 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ABT ] has closed Bollinger Bands are 17.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 104.07 - 104.43 | 104.43 - 104.76 |
| Low: | 100.64 - 101.11 | 101.11 - 101.54 |
| Close: | 102.23 - 102.88 | 102.88 - 103.48 |
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
Wed, 14 Oct 2026
Abbott Laboratories (ABT) Options Chain - Yahoo! Finance Canada
Tue, 13 Oct 2026
SimpleScreen CRC Launch Could Be A Big Moment For Abbott Stock - Simply Wall Street
Tue, 13 Oct 2026
Abbott Laboratories (ABT) stock price, news, quote and history - Yahoo Finance UK
Tue, 13 Oct 2026
Should You Add Abbott Stock to Your Portfolio Ahead of Q3 Earnings? - TradingView
Tue, 13 Oct 2026
Abbott Laboratories (ABT) Q2 2026 Earnings Call Transcript - Fortune
Mon, 12 Oct 2026
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 1,730 (M) |
| Shares Float | 1,720 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 81.7 (%) |
| Shares Short | 13,630 (K) |
| Shares Short P.Month | 22,130 (K) |
| EPS | 3.09 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 29.54 |
| Profit Margin | 11.6 % |
| Operating Margin | 14.7 % |
| Return on Assets (ttm) | 5.3 % |
| Return on Equity (ttm) | 10.5 % |
| Qtrly Rev. Growth | 13 % |
| Gross Profit (p.s.) | 15.3 |
| Sales Per Share | 26.92 |
| EBITDA (p.s.) | 6.75 |
| Qtrly Earnings Growth | -47.5 % |
| Operating Cash Flow | 9,910 (M) |
| Levered Free Cash Flow | 7,210 (M) |
| PE Ratio | 33.87 |
| PEG Ratio | 1.8 |
| Price to Book value | 3.55 |
| Price to Sales | 3.9 |
| Price to Cash Flow | 18.33 |
| Dividend | 0.62 |
| Forward Dividend | 0 |
| Dividend Yield | 0.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|